In addition to the modest reduction in drinking associated with nalmefene, its approval was controversial. The evidence supporting the registration has been criticized because the evidence of efficacy was limited to a subgroup of patients defined retrospectively, the outcome measures and sensitivity analyses were not defined a priori, and the drug was compared only to a placebo, rather than to an active comparator like naltrexone.52
